HCA Healthcare faced several rating downgrades and financial outlook revisions throughout July. Barclays lowered its rating while Wells Fargo reduced its price target due to uncertainties surrounding patient volumes. The company also cut its 2026 EPS guidance to a range of $28.70–$30.50, citing persistent policy pressures, an increase in uninsured patients, and shifts in the payer mix.
